A. K. Roy

Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?

William B. Downs, K. Blum, P. Thanos, 2021, International journal of environmental research and public health.

Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence.

Thomas J. H. Chen, K. Blum, M. Febo, 2018, Frontiers in bioscience.

Proposing a “Brain Health Checkup (BHC)” as a Global Potential “Standard of Care” to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of “Dopamine Homeostasis”

David E. Smith, K. Blum, J. Cadet, 2022, International journal of environmental research and public health.

Neurobiology and Spirituality in Addiction Recovery.

K. Blum, D. Barh, R. Badgaiyan, 2021, Acta scientific neurology.

A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone

David E. Smith, K. Blum, M. Oscar-Berman, 2018, Substance use & misuse.

Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation.

David E. Smith, K. Blum, M. Febo, 2015, Journal of child and adolescent psychopharmacology.